SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Boston Scientific Corp – ‘8-K’ for 3/3/21

On:  Wednesday, 3/3/21, at 7:05am ET   ·   For:  3/3/21   ·   Accession #:  1104659-21-31097   ·   File #:  1-11083

Previous ‘8-K’:  ‘8-K’ on / for 3/1/21   ·   Next & Latest:  ‘8-K’ on 3/11/21 for 3/9/21

Magnifying glass tilted right emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/03/21  Boston Scientific Corp            8-K:8,9     3/03/21   12:296K                                   Toppan Merrill/FA

Current Report   —   Form 8-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     38K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     17K 
 8: R1          Cover                                               HTML     53K 
10: XML         IDEA XML File -- Filing Summary                      XML     12K 
 7: XML         XBRL Instance -- tm218538d1_8k_htm                   XML     21K 
 9: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 4: EX-101.DEF  XBRL Definitions -- bsx-20210303_def                 XML     75K 
 5: EX-101.LAB  XBRL Labels -- bsx-20210303_lab                      XML    104K 
 6: EX-101.PRE  XBRL Presentations -- bsx-20210303_pre               XML     72K 
 3: EX-101.SCH  XBRL Schema -- bsx-20210303                          XSD     15K 
11: JSON        XBRL Instance as JSON Data -- MetaLinks               27±    36K 
12: ZIP         XBRL Zipped Folder -- 0001104659-21-031097-xbrl      Zip     21K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX:   C:   C:   C:   C:   C:   C:   C:   C:   C: 
 i 0000885725  i false 0000885725 2021-03-03 2021-03-03 0000885725 us-gaap:CommonStockMember 2021-03-03 2021-03-03 0000885725 bsx:SeniorNoteDue2027Member 2021-03-03 2021-03-03 0000885725 bsx:A550MCPSSeriesAMember 2021-03-03 2021-03-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

     

 

FORM  i 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

     

 

Date of Report (Date of earliest event reported):  i March 3, 2021

 

 i BOSTON SCIENTIFIC CORPORATION

(Exact name of registrant as specified in its charter)

 

 i Delaware    i 1-11083    i 04-2695240
(State or other jurisdiction of
incorporation)
  (Commission File Number)   (IRS Employer Identification No.)

 

 i 300 Boston Scientific Way,  i Marlborough,  i Massachusetts    i 01752-1234
(Address of principal executive offices)   (Zip Code)

 

( i 508)  i 683-4000

(Registrant's telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 i  Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 i  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 i  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 i  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
 i Common Stock, $0.01 par value per share    i BSX    i New York Stock Exchange
 i 0.625% Senior Notes due 2027    i BSX27    i New York Stock Exchange
 i 5.50% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share    i BSX PR A    i New York Stock Exchange

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company    i 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   

 

 

 C: 

 

 

 

ITEM 8.01 OTHER EVENTS.

 

On March 3, 2021, Boston Scientific Corporation (the "Company") announced that it has entered into a definitive agreement to acquire Lumenis LTD. (“Lumenis”), a privately-held company that develops and commercializes energy-based medical solutions, for an upfront cash payment of $1.07 billion subject to closing adjustments. The Company will exclusively acquire the Lumenis global Surgical business unit of innovative laser systems and fibers used for urology and otolaryngology procedures, as Lumenis plans to separate its Aesthetics and Ophthalmology business units into a new entity prior to the close of the acquisition. The Company expects to complete the transaction in the second half of 2021, subject to customary closing conditions.

 

A copy of the Company's press release announcing the signing of a definitive agreement to acquire Lumenis is included as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference; provided, however, that information on or connected to our website or the website of any third-party hyperlinked from or referenced in the Company's press release included as Exhibit 99.1 to this Current Report on Form 8-K is expressly not incorporated by reference into or intended to be filed as a part of this Current Report on Form 8-K.

 

Cautionary Statement Regarding Forward-Looking Statements

 

This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend” and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans, regulatory approvals, the closing of the acquisition and timing of such closing, product development and product performance and impact. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

 

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

 

Use of Non-GAAP Financial Measures

 

To supplement our consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (loss), adjusted net income (loss) available to common stockholders and adjusted net income (loss) per share that excludes certain charges and/or credits, such as amortization expense, acquisition-related net charges (credits) and investment impairment net charges (credits). These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. Further, other companies may calculate these non-GAAP financial measures differently than we do, which may limit the usefulness of those measures for comparative purposes. For further information regarding our non-GAAP measures, see Part II, Item 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations in our most recent Annual Report on Form 10-K, which we may update in Quarterly Reports on Form 10-Q we have filed or will file hereafter.

 

ITEM 9.01.FINANCIAL STATEMENTS AND EXHIBITS.

 

(d)  Exhibits

 

 

 

 

Exhibit No.   Description
99.1   Press Release issued by Boston Scientific Corporation, dated March 3, 2021
104   Cover Page Interactive Data File – the cover page XBRL tags are embedded within the Inline XBRL document

 

 C: 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: March 3, 2021 BOSTON SCIENTIFIC CORPORATION
       
    By: /s/ Vance R. Brown
      Vance R. Brown
      Vice President and Chief Corporate Counsel

 

 C: 

 

 

 C: 

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on / For Period end:3/3/21None on these Dates
 List all Filings 
Top
Filing Submission 0001104659-21-031097   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2021 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Apr. 22, 4:35:08.2pm ET